跳转至内容
Merck

1435003

USP

甲基强的松龙

United States Pharmacopeia (USP) Reference Standard

别名:

6α-甲基泼尼松龙, 11β,17α,21-三羟基-6α-甲基-1,4-孕甾二烯-3,20-二酮, 6α-甲基-11β,17α,21-三羟基-1,4-孕甾二烯-3,20-二酮, 甲基强的松龙, 甲基泼尼松龙

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C22H30O5
CAS号:
分子量:
374.47
Beilstein:
2340300
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

methylprednisolone

製造商/商標名

USP

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

[H][C@@]12C[C@H](C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])CC[C@]4(O)C(=O)CO

InChI

1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1

InChI 密鑰

VHRSUDSXCMQTMA-PJHHCJLFSA-N

基因資訊

human ... NR3C1(2908)

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Methylprednisolone USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Methylprednisolone Sodium Succinate for Injection
  • Methylprednisolone Tablets

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

相關產品

产品编号
说明
价格

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Repr. 1B - STOT RE 2

標靶器官

Adrenal gland,Immune system

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 2


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Ornulf Paulsen et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(29), 3221-3228 (2014-07-09)
Corticosteroids are frequently used in cancer pain management despite limited evidence. This study compares the analgesic efficacy of corticosteroid therapy with placebo. Adult patients with cancer receiving opioids with average pain intensity ≥ 4 (numeric rating scale [NRS], 0 to
Richard Whitlock et al.
American heart journal, 167(5), 660-665 (2014-04-29)
Steroids may improve outcomes in high-risk patients undergoing cardiac surgery with the use of cardiopulmonary bypass (CBP). There is a need\ for a large randomized controlled trial to clarify the effect of steroids in such patients. We plan to randomize
Emilio Portaccio et al.
Journal of neurology, neurosurgery, and psychiatry, 85(8), 845-850 (2014-01-10)
To assess relapses, disability progression and the role of disease modifying drugs (DMDs) in the year after delivery in women with multiple sclerosis (MS). We prospectively followed-up pregnancies occurring between 2002 and 2008 in women with MS, recruited from 21
Robert J Fox et al.
Neurology, 82(17), 1491-1498 (2014-04-01)
RESTORE was a randomized, partially placebo-controlled exploratory study evaluating multiple sclerosis (MS) disease activity during a 24-week interruption of natalizumab. Eligible patients were relapse-free through the prior year on natalizumab and had no gadolinium-enhancing lesions on screening brain MRI. Patients
Amy L Samuels et al.
British journal of haematology, 165(1), 57-66 (2014-01-25)
Drug-resistant forms of acute lymphoblastic leukaemia (ALL) are a leading cause of death from disease in children. Up to 25% of patients with T-cell ALL (T-ALL) develop resistance to chemotherapeutic agents, particularly to glucocorticoids (GCs), a class of drug to

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门